Apellis stock jumps nearly 8% as investors look to JPM healthcare update

New York, Jan 7, 2026, 12:14 PM EST — Regular session

Apellis shares were up about 8% midday, building on a volatile start to the year for biotech stocks
The company is due to present at the J.P. Morgan Healthcare Conference on Jan. 12
Investors are watching for any commercial and pipeline updates on Syfovre and Empaveli

Apellis Pharmaceuticals shares rose nearly 8% on Wednesday, outperforming the broader market as traders positioned ahead of the company’s scheduled appearance at next week’s J.P. Morgan Healthcare Conference. Apellis

The Waltham, Massachusetts-based drugmaker said on Monday it will present on Jan. 12 at 11:15 a.m. PT, with a live webcast posted to its investor site and a replay available afterward. Big healthcare conferences often bring fresh guidance, new trial details or partnering chatter — and the tape tends to price that in early. Apellis

Apellis was last up $1.91 at $25.85 in midday trading, after touching $25.89. The stock opened at $24.02 and traded as low as $24.05, according to market data.

The company markets Syfovre, an eye injection for geographic atrophy — an advanced form of age-related macular degeneration that can lead to irreversible vision loss — and Empaveli for a rare blood disease called paroxysmal nocturnal hemoglobinuria. Competitive pressure and demand trends for Syfovre have been the key swing factors for the stock over the past year. BioPharma Dive

Apellis also posted recent insider reporting to the SEC, including Form 4 filings tied to equity awards. Those filings are common in early January and do not necessarily signal a change in executives’ views, but they can draw attention when a stock is moving. Apellis

What investors are watching next is simple: whether Apellis uses the JPM stage to sharpen its outlook on demand for Syfovre, update payor access and safety monitoring, or outline next steps for its pipeline. Any shift in tone — even without new numbers — can move a name that’s been this headline-sensitive. Apellis

There’s a clear “but” for bulls: the geographic atrophy market is competitive, and Syfovre’s uptake has been scrutinized closely since launch. Any sign of slower prescriptions, tougher reimbursement, or safety worries resurfacing could cap the rally quickly. BioPharma Dive

Shan Ahmed Khan Latest posts

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

View all

Virtu Financial (VIRT) Stock Gains Lead to Reassessed Valuation and Potential Buying Opportunity
January 28, 2026, 7:21 PM EST. Shares of Virtu Financial (VIRT) rose 15% year to date, closing at $37.49, below the fair value estimate of $42.43, indicating a 34.4% intrinsic discount. The stock has delivered a 117.3% total shareholder return over three years, driven by expanding client services and new multi-asset products boosting revenue growth and margin stability. Despite optimism, risks like increased competition from tech-driven trading firms and potential regulatory hikes in digital assets pose challenges. Analysts note a 13.2% gap to average price targets, prompting investors to weigh if the current price still offers a buying opportunity or if growth is already priced in.